{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T03:01:34Z","timestamp":1788836494787,"version":"build-2803163510"},"reference-count":107,"publisher":"European Respiratory Society (ERS)","issue":"166","license":[{"start":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T00:00:00Z","timestamp":1671580800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir Rev"],"accepted":{"date-parts":[[2022,10,18]]},"published-print":{"date-parts":[[2022,12,31]]},"abstract":"<jats:p>\n                    Pneumonia is frequently encountered in clinical practice, and Gram-negative bacilli constitute a significant proportion of its aetiology, especially when it is acquired in a hospital setting. With the alarming global rise in multidrug resistance in Gram-negative bacilli, antibiotic therapy for treating patients with pneumonia is challenging and must be guided by\n                    <jats:italic>in vitro<\/jats:italic>\n                    susceptibility results. In this review, we provide an overview of antibiotics newly approved for the treatment of pneumonia caused by Gram-negative bacilli. Ceftazidime-avibactam, imipenem-relebactam and meropenem-vaborbactam have potent activity against some of the carbapenem-resistant Enterobacterales, especially\n                    <jats:italic>Klebsiella pneumoniae<\/jats:italic>\n                    carbapenemase producers. Several novel antibiotics have potent activity against multidrug-resistant\n                    <jats:italic>Pseudomonas aeruginosa<\/jats:italic>\n                    , such as ceftazidime-avibactam, ceftolozane-tazobactam, imipenem-relabactam and cefiderocol. Cefiderocol may also play an important role in the management of pneumonia caused by\n                    <jats:italic>Acinetobacter baumannii<\/jats:italic>\n                    , along with plazomicin and eravacycline.\n                  <\/jats:p>","DOI":"10.1183\/16000617.0119-2022","type":"journal-article","created":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T04:40:23Z","timestamp":1671597623000},"page":"220119","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":53,"title":["New antibiotics for Gram-negative pneumonia"],"prefix":"10.1183","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0145-9740","authenticated-orcid":false,"given":"Matteo","family":"Bassetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Magn\u00e8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele Roberto","family":"Giacobbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Bini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Vena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2022,12,21]]},"reference":[{"key":"2024102404081322000_31.166.220119.1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-147-11-200712040-00013"},{"key":"2024102404081322000_31.166.220119.2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00582-2017"},{"key":"2024102404081322000_31.166.220119.3","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s12913-017-2069-7","article-title":"Accuracy and generalizability of using automated methods for identifying adverse events from electronic health record data: a validation study protocol","volume":"17","author":"Rochefort","year":"2017","journal-title":"BMC Health Serv Res"},{"key":"2024102404081322000_31.166.220119.4","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1056\/NEJMp1300633","article-title":"Complications of mechanical ventilation\u2013the CDC's new surveillance paradigm","volume":"368","author":"Klompas","year":"2013","journal-title":"N Engl J Med"},{"key":"2024102404081322000_31.166.220119.5","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy631"},{"key":"2024102404081322000_31.166.220119.6","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-016-2703-z"},{"key":"2024102404081322000_31.166.220119.7","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e3181a037ac"},{"key":"2024102404081322000_31.166.220119.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcna.2018.12.008"},{"key":"2024102404081322000_31.166.220119.9","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1055\/s-0040-1709137","article-title":"Emerging resistance of Gram negative pathogens in community-acquired pneumonia","volume":"41","author":"Amati","year":"2020","journal-title":"Semin Respir Crit Care Med"},{"key":"2024102404081322000_31.166.220119.10","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s41479-022-00096-z","article-title":"Multi-drug resistant Gram-negative bacterial pneumonia: etiology, risk factors, and drug resistance patterns","volume":"14","author":"Assefa","year":"2022","journal-title":"Pneumonia"},{"key":"2024102404081322000_31.166.220119.11","doi-asserted-by":"publisher","DOI":"10.1042\/EBC20160063"},{"key":"2024102404081322000_31.166.220119.12","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1097\/QCO.0000000000000685","article-title":"Treatment of extended-spectrum beta-lactamases infections: what is the current role of new beta-lactams\/beta-lactamase inhibitors?","volume":"33","author":"Bassetti","year":"2020","journal-title":"Curr Opin Infect Dis"},{"key":"2024102404081322000_31.166.220119.13","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0000000000000600"},{"key":"2024102404081322000_31.166.220119.14","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2209"},{"key":"2024102404081322000_31.166.220119.15","doi-asserted-by":"publisher","DOI":"10.1378\/chest.128.2.545"},{"key":"2024102404081322000_31.166.220119.16","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1093\/cid\/ciaa003","article-title":"Clinical efficacy of ceftolozane-tazobactam versus other active agents for the treatment of bacteremia and nosocomial pneumonia due to drug-resistant pseudomonas aeruginosa","volume":"71","author":"Vena","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2024102404081322000_31.166.220119.17","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1055\/s-0041-1740605","article-title":"New antibiotics for hospital-acquired pneumonia and ventilator-associated pneumonia","volume":"43","author":"Bassetti","year":"2022","journal-title":"Semin Respir Crit Care Med"},{"key":"2024102404081322000_31.166.220119.18","doi-asserted-by":"crossref","first-page":"25","DOI":"10.37201\/req\/s01.05.2022","article-title":"Ceftobiprole medocaril","volume":"35","author":"Mendez","year":"2022","journal-title":"Rev Esp Quimioter"},{"key":"2024102404081322000_31.166.220119.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2011.11.005"},{"key":"2024102404081322000_31.166.220119.20","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu219"},{"key":"2024102404081322000_31.166.220119.21","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-016-0418-z"},{"key":"2024102404081322000_31.166.220119.22","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2019.1667229"},{"key":"2024102404081322000_31.166.220119.23","doi-asserted-by":"crossref","first-page":"32","DOI":"10.37201\/req\/s01.09.2021","article-title":"Ceftobiprole: a clinical view","volume":"34","author":"Perez-Crespo PM","year":"2021","journal-title":"Rev Esp Quimioter"},{"key":"2024102404081322000_31.166.220119.24","doi-asserted-by":"crossref","first-page":"35","DOI":"10.37201\/req\/s01.08.2022","article-title":"Ceftolozane-tazobactam in nosocomial pneumonia","volume":"35","author":"Candel","year":"2022","journal-title":"Rev Esp Quimioter"},{"key":"2024102404081322000_31.166.220119.25","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/jpids\/piz002","article-title":"Defining the role of novel beta-lactam agents that target carbapenem-resistant Gram-negative organisms","volume":"8","author":"Tamma","year":"2019","journal-title":"J Pediatric Infect Dis Soc"},{"key":"2024102404081322000_31.166.220119.26","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00860-06"},{"key":"2024102404081322000_31.166.220119.27","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.diagmicrobio.2018.11.021","article-title":"Antimicrobial activity of ceftolozane-tazobactam tested against Gram-negative contemporary (2015\u20132017) isolates from hospitalized patients with pneumonia in US medical centers","volume":"94","author":"Carvalhaes","year":"2019","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2024102404081322000_31.166.220119.28","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz147"},{"key":"2024102404081322000_31.166.220119.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2015.07.004"},{"key":"2024102404081322000_31.166.220119.30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1556\/1886.2019.00001","article-title":"Ceftolozane\/tazobactam susceptibility testing in extended-spectrum betalactamase- and carbapenemase-producing Gram-negative bacteria of various clonal lineages","volume":"9","author":"Pazzini","year":"2019","journal-title":"Eur J Microbiol Immunol"},{"key":"2024102404081322000_31.166.220119.31","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02125-17"},{"key":"2024102404081322000_31.166.220119.32","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks246"},{"key":"2024102404081322000_31.166.220119.33","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00344-19"},{"key":"2024102404081322000_31.166.220119.34","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30403-7"},{"key":"2024102404081322000_31.166.220119.35","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy578"},{"key":"2024102404081322000_31.166.220119.36","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1186\/s13054-021-03694-3","article-title":"Ceftolozane\/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trial","volume":"25","author":"Timsit","year":"2021","journal-title":"Crit Care"},{"key":"2024102404081322000_31.166.220119.37","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/s40121-021-00491-x","article-title":"Systematic literature review of real-world evidence of ceftolozane\/tazobactam for the treatment of respiratory infections","volume":"10","author":"Puzniak","year":"2021","journal-title":"Infect Dis Ther"},{"key":"2024102404081322000_31.166.220119.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2018.11.001"},{"key":"2024102404081322000_31.166.220119.39","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1093\/cid\/ciz816","article-title":"Ceftolozane\/tazobactam vs polymyxin or aminoglycoside-based regimens for the treatment of drug-resistant Pseudomonas aeruginosa","volume":"71","author":"Pogue","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2024102404081322000_31.166.220119.40","doi-asserted-by":"crossref","first-page":"4455","DOI":"10.1038\/s41598-022-08307-9","article-title":"Ceftolozane\/tazobactam versus colistin in the treatment of ventilator-associated pneumonia due to extensively drug-resistant Pseudomonas aeruginosa","volume":"12","author":"Mogyorodi","year":"2022","journal-title":"Sci Rep"},{"key":"2024102404081322000_31.166.220119.41","doi-asserted-by":"crossref","first-page":"ofaa139","DOI":"10.1093\/ofid\/ofaa139","article-title":"Ceftolozane\/tazobactam for treatment of severe ESBL-producing Enterobacterales infections: a multicenter nationwide clinical experience (CEFTABUSE II study)","volume":"7","author":"Bassetti","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2024102404081322000_31.166.220119.42","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02286-15"},{"key":"2024102404081322000_31.166.220119.43","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00220-16"},{"key":"2024102404081322000_31.166.220119.44","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00107-16"},{"key":"2024102404081322000_31.166.220119.45","doi-asserted-by":"crossref","unstructured":"Cavallini S , Unali I , Bertoncelli A , et al. Ceftazidime\/avibactam resistance is associated with different mechanisms in KPC-producing Klebsiella pneumoniae strains. Acta Microbiol Immunol Hung 2021; in press [https:\/\/doi.org\/10.1556\/030.2021.01626].","DOI":"10.1556\/030.2021.01626"},{"key":"2024102404081322000_31.166.220119.46","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-018-0241-0"},{"key":"2024102404081322000_31.166.220119.47","unstructured":"European Medicines Agency . Zavicefta: EPAR \u2013 product information. www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/004027\/WC500210234.pdf Date last updated: 20 November 2020. Date last accessed: 15 November 2022."},{"key":"2024102404081322000_31.166.220119.48","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30747-8"},{"key":"2024102404081322000_31.166.220119.49","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3390\/antibiotics9020071","article-title":"Clinical experience with ceftazidime-avibactam for the treatment of infections due to multidrug-resistant Gram-negative bacteria other than carbapenem-resistant Enterobacterales","volume":"9","author":"Vena","year":"2020","journal-title":"Antibiotics"},{"key":"2024102404081322000_31.166.220119.50","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2018.11.015"},{"key":"2024102404081322000_31.166.220119.51","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky295"},{"key":"2024102404081322000_31.166.220119.52","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02497-17"},{"key":"2024102404081322000_31.166.220119.53","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01964-16"},{"key":"2024102404081322000_31.166.220119.54","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw636"},{"key":"2024102404081322000_31.166.220119.55","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.clinthera.2020.03.014","article-title":"Cost-effectiveness comparison of ceftazidime\/avibactam versus meropenem in the empirical treatment of hospital-acquired pneumonia, including ventilator-associated pneumonia, in Italy","volume":"42","author":"Tichy","year":"2020","journal-title":"Clin Ther"},{"key":"2024102404081322000_31.166.220119.56","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz826"},{"key":"2024102404081322000_31.166.220119.57","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2018.06.014"},{"key":"2024102404081322000_31.166.220119.58","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01405-16"},{"key":"2024102404081322000_31.166.220119.59","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz827"},{"key":"2024102404081322000_31.166.220119.60","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01801-18"},{"key":"2024102404081322000_31.166.220119.61","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz123"},{"key":"2024102404081322000_31.166.220119.62","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","article-title":"Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial","volume":"21","author":"Wunderink","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2024102404081322000_31.166.220119.63","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2024102404081322000_31.166.220119.64","unstructured":"Shionogi . Fetroja (cefiderocol). Prescribing information. www.shionogi.com\/content\/dam\/shionogi\/si\/products\/pdf\/fetroja.pdf Date last updated: November 2021. Date last accessed: 15 November 2022."},{"key":"2024102404081322000_31.166.220119.65","doi-asserted-by":"crossref","first-page":"e0214221","DOI":"10.1128\/aac.02142-21","article-title":"Cefiderocol- compared to colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii","volume":"66","author":"Falcone","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2024102404081322000_31.166.220119.66","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2020.1756775"},{"key":"2024102404081322000_31.166.220119.67","doi-asserted-by":"crossref","first-page":"632","DOI":"10.3390\/antibiotics9090632","article-title":"Treatment of bloodstream infections due to Gram-negative bacteria with difficult-to-treat resistance","volume":"9","author":"Bassetti","year":"2020","journal-title":"Antibiotics"},{"key":"2024102404081322000_31.166.220119.68","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1021\/acs.jmedchem.5b00127","article-title":"Discovery of a cyclic boronic acid beta-lactamase inhibitor (RPX7009) with utility vs class A serine carbapenemases","volume":"58","author":"Hecker","year":"2015","journal-title":"J Med Chem"},{"key":"2024102404081322000_31.166.220119.69","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01443-17"},{"key":"2024102404081322000_31.166.220119.70","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01904-17"},{"key":"2024102404081322000_31.166.220119.71","doi-asserted-by":"crossref","first-page":"S792","DOI":"10.1093\/ofid\/ofaa439.1770","article-title":"1590. Activity of meropenem-vaborbactam and single-agent comparators against Enterobacterales isolates including KPC-producing isolates, from European patients hospitalized with pneumonia including ventilator-associated pneumonia (2014\u20132019)","volume":"7","author":"Shorttidge","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2024102404081322000_31.166.220119.72","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01713-15"},{"key":"2024102404081322000_31.166.220119.73","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40121-018-0214-1","article-title":"Effect and safety of meropenem-vaborbactam versus best-available therapy in patients with carbapenem-resistant Enterobacteriaceae infections: the TANGO II randomized clinical trial","volume":"7","author":"Wunderink","year":"2018","journal-title":"Infect Dis Ther"},{"key":"2024102404081322000_31.166.220119.74","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1093\/ofid\/ofab371","article-title":"Real-world, multicenter experience with meropenem-vaborbactam for Gram-negative bacterial Infections Including carbapenem-resistant Enterobacterales and Pseudomonas aeruginosa","volume":"8","author":"Alosaimy","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2024102404081322000_31.166.220119.75","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02313-19"},{"key":"2024102404081322000_31.166.220119.76","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00642-17"},{"key":"2024102404081322000_31.166.220119.77","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02406-17"},{"key":"2024102404081322000_31.166.220119.78","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02209-16"},{"key":"2024102404081322000_31.166.220119.79","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01992-17"},{"key":"2024102404081322000_31.166.220119.80","doi-asserted-by":"crossref","first-page":"ofab320","DOI":"10.1093\/ofid\/ofab320","article-title":"Ceftolozane\/tazobactam and imipenem\/relebactam cross-susceptibility among clinical isolates of Pseudomonas aeruginosa from patients with respiratory tract infections in ICU and non-ICU wards-SMART United States 2017\u20132019","volume":"8","author":"Lob","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2024102404081322000_31.166.220119.81","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1080\/14656566.2021.1939680","article-title":"An overview of cilastatin+imipenem+relebactam as a therapeutic option for hospital-acquired and ventilator-associated bacterial pneumonia: evidence to date","volume":"22","author":"Sellares-Nadal","year":"2021","journal-title":"Expert Opin Pharmacother"},{"key":"2024102404081322000_31.166.220119.82","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0851-9"},{"key":"2024102404081322000_31.166.220119.83","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00997-19"},{"key":"2024102404081322000_31.166.220119.84","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01411-17"},{"key":"2024102404081322000_31.166.220119.85","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2019.1563071"},{"key":"2024102404081322000_31.166.220119.86","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1093\/cid\/ciz530","article-title":"RESTORE-IMI 1: a multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem\/relebactam vs colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections","volume":"70","author":"Motsch","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2024102404081322000_31.166.220119.87","doi-asserted-by":"crossref","first-page":"e4539","DOI":"10.1093\/cid\/ciaa803","article-title":"A randomized, double-blind, multicenter trial comparing efficacy and safety of imipenem\/cilastatin\/relebactam versus piperacillin\/tazobactam in adults with hospital-acquired or ventilator-associated bacterial pneumonia (RESTORE-IMI 2 study)","volume":"73","author":"Titov","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2024102404081322000_31.166.220119.88","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-198631020-00002"},{"key":"2024102404081322000_31.166.220119.89","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1093\/cid\/ciz1159","article-title":"Aztreonam combination therapy: an answer to metallo-beta-lactamase-producing Gram-negative bacteria?","volume":"71","author":"Shields","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2024102404081322000_31.166.220119.90","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01856-17"},{"key":"2024102404081322000_31.166.220119.91","unstructured":"ClinicalTrials.gov . A study to determine the efficacy, safety and tolerability of aztreonam-avibactam (ATM-AVI)\u00b1metronidazole (MTZ) versus meropenem (MER)\u00b1colistin (COL) for the treatment of serious infections due to Gram negative bacteria (REVISIT). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03329092 Date last updated: 28 October 2022."},{"key":"2024102404081322000_31.166.220119.92","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1093\/cid\/ciaa586","article-title":"Efficacy of ceftazidime-avibactam plus aztreonam in patients with bloodstream infections caused by metallo-beta-lactamase-producing Enterobacterales","volume":"72","author":"Falcone","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2024102404081322000_31.166.220119.93","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq408"},{"key":"2024102404081322000_31.166.220119.94","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02418-19"},{"key":"2024102404081322000_31.166.220119.95","unstructured":"Kostrub C , Cass R , Gotfried , et al. P1637 A double-blind, randomized, placebo-controlled study to assess the safety, tolerability, plasma pharmacokinetics and lung penetration of intravenous plazomicin in healthy subjects. ECCMID 2013, Berlin, Germany. Available from: https:\/\/elibrary.escmid.org\/"},{"key":"2024102404081322000_31.166.220119.96","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1807634"},{"key":"2024102404081322000_31.166.220119.97","unstructured":"US Food and Drug Administration , FDA briefing document: plazomicin sulfate injection. www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/Anti-InfectiveDrugsAdvisoryCommittee\/UCM606039.pdf Date late updated: 2 May 2018. Date last accessed: 15 November 2022."},{"key":"2024102404081322000_31.166.220119.98","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-016-0545-8"},{"key":"2024102404081322000_31.166.220119.99","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2017.06.022"},{"key":"2024102404081322000_31.166.220119.100","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02036-13"},{"key":"2024102404081322000_31.166.220119.101","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1177\/10600280221085551","article-title":"Efficacy of eravacycline versus best previously available therapy for adults with pneumonia due to difficult-to-treat resistant (DTR) Acinetobacter baumannii","volume":"56","author":"Scott","year":"2022","journal-title":"Ann Pharmacother"},{"key":"2024102404081322000_31.166.220119.102","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200405-644ST"},{"key":"2024102404081322000_31.166.220119.103","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/resp.13663","article-title":"Prevalence and risk factors for Enterobacteriaceae in patients hospitalized with community-acquired pneumonia","volume":"25","author":"Villafuerte","year":"2020","journal-title":"Respirology"},{"key":"2024102404081322000_31.166.220119.104","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2016.03.042"},{"key":"2024102404081322000_31.166.220119.105","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00091809"},{"key":"2024102404081322000_31.166.220119.106","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201407-305OC"},{"key":"2024102404081322000_31.166.220119.107","doi-asserted-by":"publisher","DOI":"10.1378\/chest.13-3065"}],"container-title":["European Respiratory Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/16000617.0119-2022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:05:34Z","timestamp":1740355534000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/16000617.0119-2022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,21]]},"references-count":107,"journal-issue":{"issue":"166","published-online":{"date-parts":[[2022,12,21]]},"published-print":{"date-parts":[[2022,12,31]]}},"alternative-id":["10.1183\/16000617.0119-2022"],"URL":"https:\/\/doi.org\/10.1183\/16000617.0119-2022","relation":{},"ISSN":["0905-9180","1600-0617"],"issn-type":[{"value":"0905-9180","type":"print"},{"value":"1600-0617","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,21]]}}}